학술논문

COVID-19 does not impact HLA antibody profile in a series of waitlisted renal transplant candidates
Document Type
article
Source
Human Immunology. 82(8)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Prevention
Transplantation
Infectious Diseases
Kidney Disease
Organ Transplantation
Renal and urogenital
Good Health and Well Being
Adult
Aged
COVID-19
Databases
Factual
Female
HLA Antigens
Histocompatibility
Histocompatibility Testing
Host-Pathogen Interactions
Humans
Isoantibodies
Kidney Transplantation
Male
Middle Aged
Retrospective Studies
SARS-CoV-2
Waiting Lists
Kidney transplantation
organ allocation
virtual crossmatch
sensitization
Immunology
Language
Abstract
HLA antibodies are typically produced after exposure to transplanted tissue, pregnancy, and blood products. Sensitization delays access to transplantation and preclude utilization of donor organs. Infections and vaccinations have also been reported to result in HLA antibody formation. It is not known if patients develop HLA antibodies after infection with SARS-CoV-2. Here we analyzed a series of eighteen patients waiting for kidney transplantation who had symptomatic COVID-19 disease and recovered. None of the patients in this initial series developed de novo HLA antibodies. Notably, there was no increase in preexisting HLA antibodies in four highly sensitized patients with a CPRA > 80%. These preliminary data suggest that there may not be a need to repeat HLA antibody testing or perform a physical crossmatch on admission serum before kidney transplant for COVID-19 recovered patients. Data from a large number of patients with different demographics needed.